- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04504955
Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for patients with atopic dermatitis under the care of a licensed dermatologist or qualified physician extender. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Condition or disease :
Atopic Dermatitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The objective of the Corrona Atopic Dermatitis (AD) Registry is to create a national cohort of patients with atopic dermatitis. Data collected will be used to extensively evaluate the effectiveness and safety of medications used to treat atopic dermatitis. This will be done through the standardized collection of patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), and the prevalence and incidence of comorbidities and adverse events, medication utilization patterns, and patient productivity measures.
The design is a prospective, non-interventional registry for patients with AD under the care of a dermatologist or qualified physician extender. Longitudinal data are collected from both patients and their treating dermatology providers during routine clinical encounters using a structured and standardized data collection method. The scope of data collection includes but is not limited to patient demographics, disease phenotype, duration, medical history (including all prior and current treatments for AD), smoking status, alcohol use, disease activity and severity, as well as other clinician- and patient-reported outcomes, comorbidities and adverse events, infections, hospitalizations, and other targeted safety outcomes.
After the enrollment visit, AD patients and physicians will complete the follow-up questionnaires during regularly scheduled clinical encounters. The goal is to collect data from patients and providers approximately every six-months.
Adverse events may be volunteered spontaneously by the subject or be discovered as a result of general questioning by the Investigator. During all Corrona related visits with the Investigator, subjects will be questioned regarding the occurrence of adverse events.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Waltham, Massachusetts, United States, 02451
- Corrona, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient has been diagnosed with atopic dermatitis by a dermatologist or a qualified dermatology practitioner
- Patient is at least 18 years of age or older
- Patient is willing to provide Personal Information
Patient meets ONE (1) of the following conditions at the time of enrollment:
- Has started taking a new Eligible Medication within the 12 months prior to the Enrollment visit.
- Is prescribed a new Eligible Medication at the Enrollment visit.
- Is NOT being treated with an Eligible Medication at the time of enrollment but has an Eczema Area Severity Index score ≥ 12 AND a Validated Investigator Global Assessment scale for Atopic Dermatitis score ≥ 3.
Exclusion Criteria:
1)Patient must not be participating in or planning to participate in a double-blind randomized trial for a systemic atopic dermatitis medication. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.
Follow-Up Criteria
Registry Follow-Up data collection should be done at the time of routine clinical encounters approximately every 6 months. Routine or standard of care clinical encounters may occur in between two registry visits, but the data collected in the Follow-Up forms should cover the time period since the last registry visit.
For planning purposes, each Follow-Up visit is anchored to the date of the last eligible registry visit. A Follow-Up visit is eligible for payment if 150 days have passed since the last visit submission. A Follow-Up visit is not eligible for payment if conducted less than 150 days since the last registry visits except when the EARLY Follow-Up visit Criteria are satisfied.
EARLY Follow-Up Criteria
A registry Follow-Up visit should be conducted whenever a patient is prescribed or receiving the first dose of a new Eligible Medication even if less than 150 days have passed since the last registry visit. When the EARLY Follow-Up criteria are met, the next anticipated registry visit is calculated from the date of the Early Follow-Up visit.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Atopic Dermatitis
Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible
|
Observational Non-Interventional Registry
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AD epidemiology, presentation, natural history, management, and outcomes
Time Frame: Through Study completion, an average of 10years
|
The major clinical outcomes include an assessment of the epidemiology of Atopic Dermatitis; to better understand the presentation, natural history, management and outcomes.
|
Through Study completion, an average of 10years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with history of comorbidities
Time Frame: at registry enrollment
|
at registry enrollment
|
|
Physician reported: validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD)
Time Frame: every 6 months for 10 years
|
Score: 0-4, with high score indicating widespread of atopic dermatitis
|
every 6 months for 10 years
|
Physician reported: Nail changes due to atopic dermatitis (graduated VAS)
Time Frame: every 6 months for 10 years
|
Scale - 0 (Clear/Normal) to 100 (Severe Abnormalities).
Lower numbers are for mild abnormalities in a few nails, higher numbers are for more severe changes in many nails
|
every 6 months for 10 years
|
Physician reported: Atopic dermatitis body surface area (BSA)
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Physician reported: Eczema Area and Severity Index (EASI) (calculated)
Time Frame: every 6 months for 10 years
|
The severity of each sign will be graded on a scale of 0 to 3: (0) None, (1) Mild, (2) Moderate, (3) Severe.
|
every 6 months for 10 years
|
Physician reported : SCORing Atopic Dermatitis index (SCORAD) (calculated)
Time Frame: every 6 months for 10 years
|
The severity of each sign will be graded on a scale of 0 to 3: (0) None, (1) Mild, (2) Moderate, (3) Severe.
For the Overall Score [SCORAD], select a lesion that that is representative of the body and score using the same severity scale
|
every 6 months for 10 years
|
Patient reported: Patient global assessments of disease control and severity
Time Frame: every 6 months for 10 years
|
This determines the progression & severity of the disease
|
every 6 months for 10 years
|
Patient reported: Patient Oriented Eczema Measure (POEM)
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Peak pruritus (itch) NRS
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Skin pain NRS
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Fatigue NRS
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Dermatology Life Quality Index (DLQI)
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Work Productivity and Activity Impairment (WPAI)
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Atopic dermatitis control tool (ADCT)
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Itch triggers (PROMIS)
Time Frame: every 6 months for 10 years
|
every 6 months for 10 years
|
|
Patient reported: Sleeplessness and average pruritus (itch) NRS (SCORAD)
Time Frame: 6 months for 10 years
|
6 months for 10 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Corrona-AD-550
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Observational Non-Interventional Registry
-
University of BolognaEnrolling by invitationMyocardial Infarction | Coronary Disease | Acute Coronary Syndrome | Unstable Angina PectorisItaly
-
Össur EhfRegion SkaneRecruitingKnee OsteoarthritisSweden
-
Prof. Dr. Juergen WolfCharite University, Berlin, Germany; University Hospital, Essen; Goethe University and other collaboratorsRecruitingCarcinoma, Non-Small-Cell LungGermany
-
University of JordanCompletedAppendicitis | Pediatric Disorder | Hydrocele | ERASJordan
-
EpividianRecruitingLiver Diseases | Cardiovascular Diseases | Rheumatic Diseases | Neurodegenerative Diseases | Inflammatory Bowel Diseases | HIV/AIDS | Chronic DiseaseUnited States
-
University Hospital, RouenRecruitingDyspepsia | Irritable Bowel Syndrome | Functional Constipation | Faecal IncontinenceFrance
-
Vanderbilt University Medical CenterNational Institutes of Health (NIH); National Institute of General Medical...Active, not recruitingDelirium | Critical Illness | Cognitive Impairment | Trauma | Traumatic Brain Injury | ICU | Polytrauma | Alzheimer; Early OnsetUnited States
-
AIO-Studien-gGmbHTakeda; Prof. Hartmut Link; MMF GmbH; AIO AG Supportivtherapie; AGSMO (Arbeitsgemeinschaft...CompletedSecondary Immunodeficiencies (SID)Germany
-
AstraZenecaCompletedBreast Cancer | Oncology | EpidemiologyAlgeria
-
AIO-Studien-gGmbHProf. Hartmut Link; MMF GmbH; AIO AG Supportivtherapie; AGSMO (Arbeitsgemeinschaft...CompletedSolid Tumor | Anemia, Iron Deficiency | Malignant LymphomaGermany